243 related articles for article (PubMed ID: 11814765)
1. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC
Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
Blondeau JM; Vaughan D; Laskowski R; Borsos S;
Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
Marchese A; Debbia EA; Schito GC
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
Rittenhouse S; McCloskey L; Broskey J; Niconovich N; Jakielaszek C; Poupard J; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
[TBL] [Abstract][Full Text] [Related]
7. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
8. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):139-42. PubMed ID: 10863108
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Jones RN; Biedenbach DJ
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
[TBL] [Abstract][Full Text] [Related]
12. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
[TBL] [Abstract][Full Text] [Related]
14. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
16. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
Smayevsky J; Lopez H; Di Chiara M; Scarano S; Lanza A; Vilches V; Stepanik D; Bantar C; Sucari A
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):261-4. PubMed ID: 10974577
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
18. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
Thornsberry C; Jones ME; Hickey ML; Mauriz Y; Kahn J; Sahm DF
J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
Boswell FJ; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Oct; 50(4):495-502. PubMed ID: 12356793
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
